Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Reamberin in Diabetic Ketoacidosis
NCT06955416Phase 3Recruiting
- Sponsor
- POLYSAN
- Start
- May 2025
- Primary completion
- Dec 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in diabetic ketoacidosis (DKA) comparing Reamberin with Placebo (2 arms). Primary endpoint: Time from initiation of therapy to resolution of diabetic ketoacidosis at 48 hours. Started May 2025; status: recruiting.
02
Drugs
meglumine sodium succinate
03
Conditions
diabetic ketoacidosis (DKA)
Beyond the preview
Go deeper on NCT06955416.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06955416.